published : 25 Jan 2021 at 16:15
8
Siam Bioscience Co., Ltd., the first and only biopharmaceuticals manufacturer in Thailand, was founded in 2009 to preserve and continue what His Majesty the Late King Rama IX started on behalf of the Thai people’s health and wellbeing.
The company’s main products are biopharmaceuticals. Its first product was erythropoietin (EPO) which is used to treat chronic renal failure patients who can no longer produce sufficient red blood cells, resulting in anaemia. Its second product was filgrastim (GCSF) for cancer patients receiving chemotherapy, who have high risk of infection due to low white blood cell counts. Manufactured using state-of-the-art biotechnology, both of these medicines are effective treatments with low side effects.
AFP
A government official has lodged a complaint accusing a banned opposition leader of committing royal defamation and a computer crime through online comments where he expressed concerns about national efforts to acquire coronavirus vaccines.
Thanathorn Juangroongruangkit, the leader of the Future Forward Party and an icon of the Thai pro-democracy movement, was the target of the complaint by Newin Chorchaithip, the deputy minister for Digital Economy and Society, on Wednesday.
The complaint, filed with the police’s Technology Crime Suppression Division, accused Thanathorn of disseminating false criticisms of the government’s acquisition plan for COVID-19 vaccines. No charges had been filed as of Thursday, according to authorities.
AstraZeneca vaccine approved, 50,000 doses due in February
46
published : 21 Jan 2021 at 18:28
46 A nurse shows a vial of AstraZeneca s CoviShield vaccine during the coronavirus disease vaccination campaign at a medical centre in Mumbai on Saturday. (Reuters photo)
The Food and Drug Administration (FDA) has approved the emergency use of AstraZeneca Covid-19 vaccine and 50,000 doses of it will arrive in Thailand in February.
FDA secretary-general Paisarn Dunkum said on Thursday that the FDA approved the registration of the vaccine, produced in Italy by AstraZeneca Co, on Wednesday after the firm had submitted nearly 10,000 pages of its documents for vaccine registration for emergency use on Dec 22 last year.